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Cyclosporine is an 11-amino acid cyclic peptide pro-
duced by fungi such as Beauveria nivea in nature. Cyclo-
sporine exerts immunosuppressive effects through binding 
to cyclophilin of T-lymphocytes. The cyclosporine and 
cyclophilin complex inhibits calcineurin that activates the 
downstream cascades required for the transcription of in-
terleukin-2, CD40 ligand, and Fas ligand, all of which are 
necessary for proper immune function [1].
Cyclosporine use for uveitis was first reported by Nus-
senblatt et al. [2] in 1983, and first applied clinically for 
renal transplantation in 1978 [3]. Afterwards, many stud-
ies ascertained the efficacy of cyclosporine in idiopathic 
uveitis, Vogt-Koyanagi-Harada disease, birdshot retino-
choroidopathy, serpiginous choroiditis, and multifocal 
choroiditis and panuveitis, as well as in cases resulting 
from Behcet disease. However, only a few studies were 
performed in randomized, controlled, clinical trials, while 
most were retrospective case series [4-21].
In Korea, however, only two case series are currently 
available for the result of cyclosporine use in endogenous 
uveitis, where each treated only 15 patients for a rather 
short period of six to 18 months [22,23]. Thus, we present 
the long term results from a large group of Korean patients 
with regard to cyclosporine use for treatment of endog-
enous uveitis.
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Purpose: To assess the clinical outcomes of cyclosporine treatment for noninfectious uveitis
Methods: A retrospective review of medical records was completed for 182 noninfectious uveitis patients who 
were treated with cyclosporine between January 2001 and August 2010. Data was obtained relevant to demo-
graphic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage 
of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uve-
itic activity, and adverse effects during the cyclosporine use.
Results: Uveitic activity was controlled to a level of minimal inflammation in 89.0% and completely in 78.6% of 
patients by the median duration of 49 and 98 days, respectively. Prednisolone-sparing (dose ≤10 mg) control 
of inflammation equal to or less than the minimal activity was achieved in 75.3% of patients. VA was aggravat-
ed more than 0.2 logarithm of the minimum angle of resolution in 17.3% of eyes in spite of cyclosporine treat-
ment for the mean follow-up of 698.4 days. Dose reduction and cessation of cyclosporine was required only 
in 3.3% and 9.3%, respectively, due to the intolerable toxicity, although 44.0% of patients experienced mild to 
moderate adverse effects.
Conclusions: Cyclosporine combined with corticosteroids or other immunosuppressive drugs as needed is an 
effective treatment for noninfectious uveitis, thus minimizing the adverse effects of corticosteroids and other 
toxic drugs. However, careful monitoring for the toxicity of cyclosporine is needed, because a small group of 
patients cannot tolerate its toxicity.
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Materials and Methods
A list of patients for whom cyclosporine was prescribed 
to manage endogenous uveitis was extracted from the da-
tabase of Seoul National University Hospital between 2001 
and 2010. Two hundred patients with endogenous uveitis 
were managed with cyclosporine during the period and 18 
patients were excluded from the study since cyclosporine 
treatment was started at other clinics. A retrospective re-
view of medical records was completed for 182 noninfec-
tious uveitis patients who were treated with cyclosporine 
between January 2001 and August 2010.
Cyclosporine was used when corticosteroids were insuf-
ficient to control uveitic activity, corticosteroid side effects 
were anticipated because of long-term use of high dose, or 
other immunosuppressive treatment failed to suppress the 
patient’s inflammation. Cyclosporine was administered 
at a dose of ≤5 mg/kg/day, and the dose was adjusted ac-
cording to uveitic activity following a tapering of cortico-
steroids. Adverse effects were regularly monitored with 
reports of a patient’s discomforts, blood pressure, complete 
blood count with differentiation, renal function, liver func-
tion, and serum electrolyte as recommended [24].
Data was obtained relevant to demographic information, 
anatomic location, and specific diagnosis of uveitis. More-
over, we took note of systemic disorder, laterality of the 
inflammation, dosage of cyclosporine and prednisolone, 
usage of other immunosuppressive drugs, visual acuity 
(VA), uveitic activity before and after treatment, and ad-
verse effects to the time when cyclosporine was discontin-
ued or the last follow-up was reached. Uveitic activity was 
classified as “inactive”, “slightly active”, or “active”, where 
any active posterior uveitis was noted as “active”, while 
“slightly active” meant trace cells in the anterior chamber 
or the vitreous, or a trace haze of the vitreous [25]. If both 
eyes were involved, the uveitic activity in a more severe 
eye was recorded.
Averages and frequencies were calculated for each vari-
able, while Kaplan-Meier survival analysis was applied for 
time to an inflammation control to “slightly active” or “in-
active”, and for time to a cessation of cyclosporine due to 
adverse effects. Decimal VA was converted into logarithm 
of the minimum angle of resolution (logMAR) for calcu-
lation. SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) was 
employed for statistical analyses. 
This study was approved by the Institutional Review 
Board at Seoul National University Hospital and adhered 
to the tenets of the Declaration of Helsin ki.
Results
The mean age of the patients was 44.6 ± 12.3 years 
(range, 17 to 77 years) and 99 patients (54.4%) were male. 
The mean duration of cyclosporine use was 698.4 ± 705.8 
days (range, 30 to 3,303 days). Anatomic classification and 
specific diagnosis of uveitis treated with cyclosporine in 
our study are presented in Table 1. Panuveitis and Behcet 
disease-related uveitis were the most common anatomic 
location (74.2%) and specific diagnosis (48.4%) of uveitis, 
respectively, while panuveitis present in Behcet disease 
was the most common specific disease entity (40.7%) treat-
ed with cyclosporine. One-hundred twenty-three patients 
(67.6%) in our study had uveitis in both eyes.
Cyclosporine was started at a mean dose of 164.2 ± 51.3 
mg (range, 50 to 300 mg) together with prednisolone (mean, 
19.5 ± 13.1 mg; range, 0 to 60 mg) in 161 patients (88.5%) 
and other immunosuppressive drugs in 46 patients (25.3%). 
Immunosuppressive drugs used before commencing cyclo-
Table 1. Anatomic classification and specific diagnosis of uveitis treated with cyclosporine
Specific diagnosis of uveitis
Anatomic classification
Total Anterior 
uveitis
Anterior and 
intermediate 
uveitis
Intermediate 
uveitis
Posterior 
uveitis Panuveitis
Ankylosing spondylitis-related uveitis   2 (1.1) 0 0 0   1 (0.5)   3 (1.6)
HLA-B27-related uveitis   3 (1.6)   1 (0.5) 0 0 0   4 (2.2)
Behcet disease-related uveitis   2 (1.1)   9 (4.9) 0   3 (1.6)   74 (40.7)   88 (48.4)
Idiopathic uveitis   7 (3.8)   3 (1.6) 6 (3.3)   9 (4.9)   43 (23.6)   68 (37.4)
Sarcoidosis-related uveitis   1 (0.5) 0 0 0 0   1 (0.5)
Serpiginous choroiditis 0 0 0   1 (0.5) 0   1 (0.5)
Sympathetic ophthalmia 0 0 0 0   1 (0.5)   1 (0.5)
Vogt-Koyanagi-Harada disease 0 0 0 0   16 (8.8)   16 (8.8)
Total   15 (8.2)   13 (7.1) 6 (3.3)   13 (7.1)   135 (74.2)   182 (100.0)
Values are presented as number (%).23
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sporine included: azathioprine in 12 patients (6.6%), colchi-
cine in six patients (3.3%), methotrexate in three patients 
(1.6%), and a combination of azathioprine and colchicine 
in three patients (1.6%); of these 24 patients, 18 patients 
continued their immunosuppressive treatment or changed 
to a drug other than cyclosporine. The mean dose of cy-
closporine at the time of discontinuation or the last follow-
up was 126.9 ± 61.5 mg (range, 25 to 300 mg). Ninety-one 
patients (50.0%) were still taking cyclosporine at the last 
follow-up, while 61 patients (33.5%) discontinued use and 
30 patients (16.5%) were missing, where the mean duration 
of cyclosporine use was 905.2 ± 789.0 days (range, 122 to 
3,303 days), 564.6 ± 585.8 days (range, 30 to 2,579 days), 
and 343.5 ± 406.6 days (range, 30 to 1,736 days), respec-
tively. Adverse effects were the reason for cyclosporine 
discontinuation in five of 61 patients.
Uveitic activity was controlled to a level equal to or less 
than “slightly active” in 89.0% of patients by the median 
time of 49 days (range, 0 to 945 days; cyclosporine was 
added to one patient with “slightly active” uveitis), where 
35.2%, 71.6%, and 87.0% of patients achieved this level of 
inflammation by the first one, three, and six months, re-
spectively. The mean doses of cyclosporine and predniso-
lone were 166.7 ± 52.3 mg (range, 50 to 300 mg) and 15.9 
± 10.5 mg (range, 0 to 60 mg), respectively, while 30.8% 
of patients were taking other immunosuppressive drugs. 
“Inactive” uveitis was shown in 78.6% of patients by the 
median time of 98 days (range, 7 to 1,146 days), where 
16.1%, 47.6%, and 73.4% of patients achieved this complete 
resolution of uveitis by the first one, three, and six months, 
respectively. The mean doses of cyclosporine and pred-
nisolone at the time of first “inactive” uveitis were 163.3 ± 
52.4 mg (range, 50 to 300 mg) and 13.5 ± 9.2 mg (range, 0 
to 50 mg), respectively, while 31.3% used other immuno-
suppressive drugs simultaneously. Achievements of these 
levels of uveitis resolution according to time were dem-
onstrated from Kaplan-Meier survival analyses in Fig. 1. 
Corticosteroid-sparing (prednisolone dose ≤10 mg) control 
of inflammation equal to or less than “slightly active” was 
achieved in 75.3% of patients.
One-hundred ten patients who showed a control of 
inflammation equal to or less than “slightly active” had 
experienced recurrence of “active” uveitis after a median 
duration of 83 days (range, 10 to 546 days) from the time 
when “slightly active” states were achieved. At the recur-
rence of “active” uveitis, the mean doses of cyclosporine 
and prednisolone were 148.0 ± 55.7 mg (range, 0 to 300 mg; 
one patient experienced “active” uveitis after cessation of 
cyclosporine) and 8.9 ± 6.0 mg (range, 0 to 25 mg), respec-
tively. 
In the last medical records considered in our study, 82 
patients (45.1%), 41 patients (22.5%), and 59 patients (32.4%) 
showed “inactive”, “slightly active”, and “active” uveitis, 
respectively. VA at the last follow-up was aggravated by 
more than 0.2 logMAR in 17.3% of eyes in spite of cyclo-
sporine treatment during the study time.
Adverse effects were experienced by 44.0% of patients, 
which are tabulated in Table 2. Hyperglycemia was the 
most common adverse effects in 25.3% of patients, while 
nephropathy was observed only in two patients. Dose re-
duction and cessation of cyclosporine was required only in 
3.3% and 9.3% of patients respectively, due to the intoler-
able toxicity. This result is visualized with Kaplan-Meier 
survival curve in Fig. 2.
Fig. 1. Kaplan-Meier survival curve showing the uveitis con-
trol against time. The upper curve denotes a level equal to or 
less than “slightly active” and the lower curve denotes a level 
of “inactive”.
Table 2. Adverse effects of cyclosporine used for endogenous 
uveitis
Adverse effects % of patients
None 56.0
Edema 1.0
Gastrointestinal problem 7.5
Gingival hyperplasia 0.5
Hepatotoxicity 7.1
Hyperglycemia 25.3
Hypertension 6.6
Hypertrichosis 4.9
Nephrotoxicity 1.0
Neuropathy 0.5
Paresthesia 2.6
Sensation of heating-up 0.524
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Discussion
Cyclosporine was effective for endogenous uveitis by re-
ducing a uveitic inflammation to “slightly active” in 89.0% 
of patients and to “inactive” in 78.6% of patients. Most 
patients achieved these effects by six months in 87.0% for 
“slightly active” and 73.4% for “inactive” uveitis. Only 
17.3% of patients experienced visual loss of more than 0.2 
logMAR at the last follow-up when considering the sever-
ity of uveitis that could not be managed with a sole treat-
ment using corticosteroid.
Previous studies reported similar or inferior effective-
ness of cyclosporine for ocular inflammatory disease com-
pared to our study [2,6-9,12-14,17,20,21,26]. This disparity 
comes from the differences in outcome measures and the 
definition of success in uveitis control, thus making di-
rect comparison between studies impossible. We did not 
consider maintenance of partial or complete resolution of 
inflammation when deciding a treat ment success, and in-
cluded the patients who concurrently took other immuno-
suppressive drugs. Thus, our study showed superior effec-
tiveness of cyclosporine in endogenous uveitis compared to 
the ones with a stricter measure of success [12,20,26]. As 
an input, we considered the uveitic activity based upon the 
eye with more severe inflammation when bilateral uveitis 
was encountered since systemic cyclosporine was applied 
to a patient, which, on the contrary, might decrease the 
success rate of cyclosporine.
The shortest duration of follow-up was 30 days in our 
study. We did not limit the follow-up time for exclusion, 
because the quickest time for a resolution of uveitis to 
“slightly active” or “inactive” was seven days. Since 9.9% 
of patients in our study used cyclosporine for less than 
three months, this fact may have decreased the rate of suc-
cess or adverse effects observed in this study.
Overall, many patients (110 of 162 patients, 67.9%) ex-
perienced recurrence of “active” uveitis after achieving 
equal to or less than “slightly active” uveitis. This might 
be attributed not only to the reduced dose of cyclosporine 
and corticosteroids, but also to the limitation in sustained 
suppression of uveitis with cyclosporine or the clinical fea-
tures of included uveitis.
Only a small group of patients in our study discontinued 
cyclosporine due to toxicity, which is superior to other 
studies that reported adverse effects with low-dose cyclo-
sporine for ocular inflammation [17,20,21,27]. We used a 
protocol of relatively rapid cyclosporine dose reduction 
according to inflammation status, which might have also 
contributed the lower rates of toxicity. In addition, more 
adverse effects might be found in the 16.5% of missed pa-
tients, which also decreased the observed adverse effects.
The limitations of our study are obvious as it is a retro-
spective study. The usage of cyclosporine and other drugs 
were not controlled and compliance could not be assessed. 
The results may not be applied to a general population, 
because uveitis with worse prognosis tended to be included 
as a tertiary referral center. In addition, there might be 
disparities between retinologists in the grading of uveitic 
inflammation that could cause an error in data analyses.
In conclusion, cyclosporine combined with corticoste-
roids or other immunosuppressive drugs as needed is ef-
fective for endogenous uveitis, via minimizing the adverse 
effects of corticosteroids and other toxic drugs. However, 
careful monitoring for cyclosporine toxicity also is needed.
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